Genprex Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Genprex's earnings have been declining at an average annual rate of -19.4%, while the Biotechs industry saw earnings growing at 19% annually.
Belangrijke informatie
-19.4%
Groei van de winst
7.2%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | n/a |
Rendement op eigen vermogen | -601.6% |
Nettomarge | n/a |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?
Aug 16Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation
Jan 31Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Oct 12Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
Aug 15We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate
Jun 14Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Feb 09Genprex: Limited Clinical Data To Justify Risk
Nov 19We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth
Oct 27Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Jun 11Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%
May 05Genprex' stock jumps after corporate update
Feb 01Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Jan 13Genprex completes manufacturing scale-up of lung cancer therapy
Dec 22Opbrengsten en kosten
Hoe Genprex geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -26 | 13 | 13 |
31 Mar 24 | 0 | -28 | 12 | 16 |
31 Dec 23 | 0 | -31 | 13 | 18 |
30 Sep 23 | 0 | -31 | 14 | 17 |
30 Jun 23 | 0 | -30 | 14 | 16 |
31 Mar 23 | 0 | -28 | 13 | 15 |
31 Dec 22 | 0 | -24 | 12 | 12 |
30 Sep 22 | 0 | -24 | 12 | 12 |
30 Jun 22 | 0 | -21 | 11 | 10 |
31 Mar 22 | 0 | -19 | 11 | 9 |
31 Dec 21 | 0 | -21 | 12 | 9 |
30 Sep 21 | 0 | -19 | 12 | 7 |
30 Jun 21 | 0 | -18 | 11 | 7 |
31 Mar 21 | 0 | -19 | 11 | 8 |
31 Dec 20 | 0 | -18 | 11 | 7 |
30 Sep 20 | 0 | -15 | 10 | 5 |
30 Jun 20 | 0 | -15 | 10 | 5 |
31 Mar 20 | 0 | -14 | 11 | 3 |
31 Dec 19 | 0 | -11 | 9 | 2 |
30 Sep 19 | 0 | -12 | 10 | 2 |
30 Jun 19 | 0 | -11 | 10 | 2 |
31 Mar 19 | 0 | -14 | 12 | 1 |
31 Dec 18 | 0 | -12 | 11 | 1 |
30 Sep 18 | 0 | -10 | 9 | 1 |
30 Jun 18 | 0 | -8 | 8 | 0 |
31 Mar 18 | 0 | -3 | 3 | 0 |
31 Dec 17 | 0 | -3 | 3 | 0 |
30 Sep 17 | 0 | -4 | 3 | 0 |
30 Jun 17 | 0 | -4 | 3 | 0 |
31 Mar 17 | 0 | -5 | 4 | 0 |
31 Dec 16 | 0 | -4 | 4 | 0 |
Kwaliteitswinsten: GNPX is currently unprofitable.
Groeiende winstmarge: GNPX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: GNPX is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.
Versnelling van de groei: Unable to compare GNPX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: GNPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: GNPX has a negative Return on Equity (-601.59%), as it is currently unprofitable.